Your browser doesn't support javascript.
loading
Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution.
Chan-Seng-Yue, Michelle; Kim, Jaeseung C; Wilson, Gavin W; Ng, Karen; Figueroa, Eugenia Flores; O'Kane, Grainne M; Connor, Ashton A; Denroche, Robert E; Grant, Robert C; McLeod, Jessica; Wilson, Julie M; Jang, Gun Ho; Zhang, Amy; Dodd, Anna; Liang, Sheng-Ben; Borgida, Ayelet; Chadwick, Dianne; Kalimuthu, Sangeetha; Lungu, Ilinca; Bartlett, John M S; Krzyzanowski, Paul M; Sandhu, Vandana; Tiriac, Hervé; Froeling, Fieke E M; Karasinska, Joanna M; Topham, James T; Renouf, Daniel J; Schaeffer, David F; Jones, Steven J M; Marra, Marco A; Laskin, Janessa; Chetty, Runjan; Stein, Lincoln D; Zogopoulos, George; Haibe-Kains, Benjamin; Campbell, Peter J; Tuveson, David A; Knox, Jennifer J; Fischer, Sandra E; Gallinger, Steven; Notta, Faiyaz.
Affiliation
  • Chan-Seng-Yue M; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Kim JC; PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Wilson GW; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Ng K; Genomics Technology Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Figueroa EF; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • O'Kane GM; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Connor AA; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Denroche RE; PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Grant RC; Wallace McCain Centre for Pancreatic Cancer, Department of Medical Oncology, Princess Margaret Centre University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • McLeod J; Hepatobiliary/Pancreatic Surgical Oncology Program, University Health Network, Toronto, Ontario, Canada.
  • Wilson JM; PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Jang GH; Wallace McCain Centre for Pancreatic Cancer, Department of Medical Oncology, Princess Margaret Centre University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Zhang A; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Dodd A; PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Liang SB; PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Borgida A; PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Chadwick D; Wallace McCain Centre for Pancreatic Cancer, Department of Medical Oncology, Princess Margaret Centre University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Kalimuthu S; UHN Program in BioSpecimen Sciences, University Health Network, Toronto, Ontario, Canada.
  • Lungu I; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Bartlett JMS; UHN Program in BioSpecimen Sciences, University Health Network, Toronto, Ontario, Canada.
  • Krzyzanowski PM; Department of Pathology, University Health Network and University of Toronto, Toronto, Ontario, Canada.
  • Sandhu V; Diagnostic Development, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Tiriac H; Diagnostic Development, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Froeling FEM; Genomics Technology Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Karasinska JM; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Topham JT; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
  • Renouf DJ; Lustgarten Foundation Pancreatic Cancer Research Laboratory, Cold Spring Harbor, NY, USA.
  • Schaeffer DF; Department of Surgery, University of California San Diego, NCI-designated Comprehensive Cancer Center, La Jolla, CA, USA.
  • Jones SJM; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
  • Marra MA; Lustgarten Foundation Pancreatic Cancer Research Laboratory, Cold Spring Harbor, NY, USA.
  • Laskin J; Department of Surgery and Cancer, Imperial College London, London, UK.
  • Chetty R; Pancreas Centre BC, Vancouver, British Columbia, Canada.
  • Stein LD; Pancreas Centre BC, Vancouver, British Columbia, Canada.
  • Zogopoulos G; Pancreas Centre BC, Vancouver, British Columbia, Canada.
  • Haibe-Kains B; Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • Campbell PJ; Pancreas Centre BC, Vancouver, British Columbia, Canada.
  • Tuveson DA; Department of Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, British Columbia, Canada.
  • Knox JJ; Canada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada.
  • Fischer SE; Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
  • Gallinger S; Canada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada.
  • Notta F; Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
Nat Genet ; 52(2): 231-240, 2020 02.
Article in En | MEDLINE | ID: mdl-31932696
ABSTRACT
Pancreatic adenocarcinoma presents as a spectrum of a highly aggressive disease in patients. The basis of this disease heterogeneity has proved difficult to resolve due to poor tumor cellularity and extensive genomic instability. To address this, a dataset of whole genomes and transcriptomes was generated from purified epithelium of primary and metastatic tumors. Transcriptome analysis demonstrated that molecular subtypes are a product of a gene expression continuum driven by a mixture of intratumoral subpopulations, which was confirmed by single-cell analysis. Integrated whole-genome analysis uncovered that molecular subtypes are linked to specific copy number aberrations in genes such as mutant KRAS and GATA6. By mapping tumor genetic histories, tetraploidization emerged as a key mutational process behind these events. Taken together, these data support the premise that the constellation of genomic aberrations in the tumor gives rise to the molecular subtype, and that disease heterogeneity is due to ongoing genomic instability during progression.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Carcinoma, Pancreatic Ductal Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Nat Genet Year: 2020 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Carcinoma, Pancreatic Ductal Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Nat Genet Year: 2020 Document type: Article